Bristol-Myers Squibb Selects ZS to Support Global Commercial Analytics

EVANSTON, Ill., Sept. 21, 2015 /PRNewswire/ -- ZS – a global leader in sales and marketing consulting, outsourcing, technology and software – has been selected by global biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) to support its worldwide commercial analytics organization. Bristol-Myers Squibb will replace its previous, multiple-vendor approach with ZS as its primary vendor for commercial analytics support.

Over the course of the multi-year agreement, ZS will apply its deep analytics capabilities and more than 30 years of industry experience across more than 65 countries to benefit Bristol-Myers Squibb. 

In particular, ZS will deploy innovative analytics-engagement solutions to help Bristol-Myers Squibb deliver actionable insights that answer key business questions quickly and accurately. The firm's end-to-end, Analytics Process Optimization (APO)™ solution encompasses data management, support for all commercial analytics areas and a cloud-based infrastructure.

"We have worked with Bristol-Myers Squibb for more than 20 years, and are thrilled to work with the company to shape its analytics, infrastructure and data ecosystem," said Jaideep Bajaj, chairman of ZS. "Our vision is to help Bristol-Myers Squibb enhance its commercial effectiveness through efficient, fact-based decision making."

About ZS
ZS is the world's largest firm focused exclusively on improving business performance through sales and marketing solutions, from customer insights and strategy to analytics, operations and technology. More than 4,000 ZS professionals in 22 offices worldwide draw on deep industry and domain expertise to deliver impact where it matters for clients across multiple industries. To learn more, visit www.zsassociates.com or follow us on Twitter (@ZSAssociates) and LinkedIn.

 

SOURCE ZS



RELATED LINKS
http://www.zsassociates.com

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.